Gene therapies can have life-saving benefits for patients, but the advancements come at an enormous price tag of $850,000 to $3 million per patient.
When Hemgenix hit the market in November, it became the world’s most expensive drug at a $3.5 millionprice tag.
Drug manufacturers argue that these costs are justified when looking at the cost savings .
While plan exclusions (for members) and lasering(for self-funded companies/insurance carriers) are commonplace practices, deciding not to provide this groundbreaking coverage based on financial considerations poses a moral dilemma for health plans and insurers.
When faced with an opportunity to “cure” a serious, life-threatening disease, surely pub.
CGTs are emerging medical treatments that aim to cure a number of serious and life-threatening diseases, such as cancer and spinal muscular atrophy.
Gene therapies are typically an injection of genetically altered genes into cells in place of missing or defective ones, and cellular therapies rely on transfusions to replace diseased or dysfunctional.
Gene therapies on the market include Luxturna, Zolgensma, Zynteglo, eli-cel and Hemgenix, and 13 more could be approved in the U.S. or Europe this year.
But this is just the tip of the iceberg: Looking further down the pipeline, we see an additional 3,633 CGTs in progress, as of Q2 2022, with 200-plusin late-phase development and the potential for .
